# Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

> **NCT05945823** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Taiho Oncology, Inc.** · enrollment: 53 (actual)

## Conditions studied

- Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer
- Esophageal Adenocarcinoma
- Esophageal Squamous Cell Cancer
- Siewert Type 1 GEJ Cancer
- Pancreatic Cancer

## Interventions

- **DRUG:** Futibatinib
- **DRUG:** Pembrolizumab
- **DRUG:** Cisplatin
- **DRUG:** 5-FU
- **DRUG:** Oxaliplatin
- **DRUG:** Leucovorin
- **DRUG:** Levoleucovorin
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT05945823
- **Lead sponsor:** Taiho Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-07-13
- **Primary completion:** 2026-01-28
- **Final completion:** 2027-01
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05945823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05945823, "Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05945823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*